Capsaicin 8% Patch for Spinal Cord Injury Neuropathic Pain

Status: Active, not recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

A prospective case control study to determine the effectiveness and longevity of 8% capsaicin patch(es) in treating neuropathic pain in persons with spinal cord injury. The investigators will study spinal cord injury patients at South Texas Veterans Health Care Systems Spinal Cord Injury inpatient unit and outpatient clinics.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 99
Healthy Volunteers: Accepts Healthy Volunteers
View:

• Diagnosis of SCI

• Neuropathic pain below level of injury

• Surface area of pain no larger than 2 patches

• Failed or did not tolerate gabapentin 3600mg/day, pregabalin 600mg/day, capsaicin cream and/or lidocaine cream

• Skin over painful area intact

Locations
United States
Texas
Audie Lee Murphy VA Hospital
San Antonio
Time Frame
Start Date: April 2016
Estimated Completion Date: December 2022
Participants
Target number of participants: 11
Treatments
Experimental: Investigational Capsacin, Then Control Capsacin
Qutenza, Capsaicin 8% Patch will be used for 12 weeks followed by capsacin 0.025% Well Patch
Experimental: Control Capsacin, Then Investigational Capsacin
Active control with low dose capsaicin 0.025% Well Patch used for 12 weeks followed by Qutenza 8% Patch
Sponsors
Leads: The University of Texas Health Science Center at San Antonio

This content was sourced from clinicaltrials.gov

Similar Clinical Trials